VYJUVEK Reports $127.3M Global Revenue, Cuts Expense Guidance
What happened
VYJUVEK reported global revenue of $127.3 million, which represents a 30% increase from $97.8 million reported in the third quarter of 2025. The company also authorized a $400 million share repurchase program. Non-GAAP expense guidance was lowered to a range of $155 million to $165 million, down from the previous range of $175 million to $195 million.
From aol.com
Why it matters
The company maintained a strong financial position, reporting $1.2 billion in cash and investments. US net revenue reached $95.3 million, supported by over 760 US reimbursement approvals. Despite the revenue growth, net income per diluted share decreased to $2.05 from $2.66 in the prior year period.
From aol.com
Who's involved
- Suma KrishnanPresident of Research and Development at Krystal Biotech, Inc.
- Christine WilsonSenior Vice President and Head of US Commercial at VYJUVEK
Keep exploring
The entities involved
-
Suma Krishnan
researcher
Nothing else this week.
-
Christine Wilson
researcher ORCID ID = 0000-0003-1741-830X
Nothing else this week.